TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03112720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block
Description: The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
Study: NCT03359499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: Oral suspension administered BID

Intervention type: DRUG
Group type: OTHER
Intervention: Trimebutine
Description: One tablet of 200 mg of trimebutine administered BID
Study: NCT03656718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (IV) Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (IV) Specified Dose on Specified Days
Study: NCT02125084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study: NCT05059509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB825
Description: FB825, 5mg/kg, by 1 hour IV infusion on Day 1
Study: NCT03004612

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Linagliptin + metformin
Description: Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study: NCT00681135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)
Description: toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)
Description: toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual toothbrush (elmex® Inter X medium toothbrush)
Description: toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manual toothbrush (elmex® Inter X medium toothbrush)
Description: toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
Study: NCT04124302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glulisine
Description: A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
Study: NCT02845921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: leg elevation
Description: A stand making an angle of 30 degree to the horizontal is used to elevate both the legs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: leg wrapping
Description: Esmarch bandage is used to wrap each lower limb

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no intervention has been done
Study: NCT00424476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Study: NCT04124302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study: NCT06285578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Description: Probiotics, Lactiplantibacillus plantarum TWK10, are packaged in powder form. Each participant consume one packet every day on a fasting status for 8 weeks.
Study: NCT01454726

Intervention type: OTHER
Group type: OTHER
Intervention: drug
Description: the Western medical treatment alone.
Study: NCT04124302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study: NCT02721043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptides
Description: Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
Study: NCT05144919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of a biodiverse diet
Description: Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~1. Where to locally source inputs and expected price~2. How/when to prepare plots using organic inputs~3. Planting and best-practice management practices~4. Seed saving and storage~5. Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices
Study: NCT01982539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zipsor®
Description: Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
Study: NCT03825887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study.
Study: NCT06285578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Description: Probiotics, Lactiplantibacillus plantarum TWK10, are packaged in powder form. Each participant consume one packet every day on a fasting status for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT training
Description: HIIT training is conduct at the intensity of 85-90% VO2max for 2 minutes with 1-minute inactive resting interval, repeating for 7 times. 3 sessions per week for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT training
Description: HIIT training is conduct at the intensity of 85-90% VO2max for 2 minutes with 1-minute inactive resting interval, repeating for 7 times. 3 sessions per week for 8 weeks.
Study: NCT01350271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole polymorph A and C 500 mg
Description: Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole polymorph C
Description: Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
Study: NCT03224312

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01116063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Description: Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
Study: NCT04386850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 25-Hydroxyvitamin D3
Description: Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 25-Hydroxyvitamin D3
Description: Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
Study: NCT02890602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
Study: NCT02870153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Study: NCT04390243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study: NCT01312948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype mask (known as Pixi)
Description: This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
Study: NCT04390243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study: NCT01166126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02087865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil HCL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01928810

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: 12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
Study: NCT06285578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplementation
Description: Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.
Study: NCT03324048

Intervention type: OTHER
Group type: OTHER
Intervention: relaxation session
Description: During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y).
Study: NCT02854657

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
Study: NCT05802498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRMA
Description: For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
Study: NCT03463122

Intervention type: DEVICE
Group type: OTHER
Intervention: field of regard-focused visual exploration therapy
Description: field of regard-focused visual exploration therapy in addition to conventional therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: field of regard-focused visual exploration therapy
Description: field of regard-focused visual exploration therapy in addition to conventional therapy

Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: conventional therapy for stroke rehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: conventional therapy for stroke rehabilitation
Study: NCT06337045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex prevention and rehabilitation intervention
Description: The complex intervention started and ended with individual consultations with health professionals and furthermore included physical exercise, smoking cessation, alcohol treatment, dietary interventions, AF specific patient education, MediYoga, and/or psychosocial support.
Study: NCT02442102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and sensory stimulation
Description: 60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
Study: NCT04239976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear FitBit for gait assessment test
Study: NCT01797068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients in the standard of care group will experience the usual intake process in the ED setting.
Study: NCT01233349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Litramine
Description: 2 tablets 3 times daily (oral consumption, 30 minutes after meal)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets 3 times daily (oral consumption, 30 minutes after meal)
Study: NCT03174457

Intervention type: DRUG
Intervention: Micafungin
Description: Intravenous
Study: NCT01636011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine Treatment
Description: Osteopathic Manipulative Medicine Treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch sham
Description: Light Touch sham
Study: NCT01298362

Intervention type: DRUG
Intervention: Aromatase Inhibitors

Intervention type: DRUG
Intervention: Aromatase Inhibitors

Intervention type: DRUG
Intervention: Chemotherapy
Study: NCT00070070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TICE®-strain BCG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TICE®-strain BCG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TICE®-strain BCG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TICE®-strain BCG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT02726516

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRJ-205
Description: 1 sachet per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet per day
Study: NCT03563729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: In combination with nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: In combination with nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: In combination with nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: In combination with ipilimumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: In combination with ipilimumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: In combination with ipilimumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: In combination with binimetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: In combination with encorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: In combination with dabrafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: In combination with trametinib